Clinical trial
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00150618 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)
- Lead sponsor
- Shire
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 30, 2004
- Completion date
- October 7, 2004
- Enrollment
- 324 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.